ClinicalTrials.gg
CompletedNCT07408180Updated May 5, 2026

Exploratory Randomized, Controlled, Dose-response Study on the Impact of Nicotine From Five Variants of a Nicotine Tablet (NICOTINE TABLET) on Attention

An interventional study of NICOTINE TABLET-0mg and NICOTINE TABLET-0.5mg in Attention, sponsored by Philip Morris Products S.A.. Completed at 1 site in Sweden. Open to participants aged 19 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-05-05.

Sponsored by Philip Morris Products S.A. (part of Philip Morris International) · Not applicable, Interventional, and Other

How we know

From the registry’s dates

  • Registered 3 months after the study started (first participant enrolled Oct 2025, registered Feb 2026).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
19 Years to 60 Years
Sex
All
01

Study summary

This study aims to provide initial insights into the impact of orally delivered nicotine on attentional performance in adult occasional users of nicotine pouches. Nicotine will be administered via a dissolvable tablet for approximately 10 minutes. The main objective of this exploratory study is to characterize the effect of nicotine on attentional performance, using metrics derived from Continuous Performance Test (CPT).

Additionally, a second CPT assessment will be conducted two hours after the first administration to explore the potential sustained effects of nicotine on attention as an exploratory objective.

02

Conditions studied

  • Attention
03

In context

Lead sponsor

Philip Morris Products S.A. is the lead sponsor of 49 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
19 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subject is able to understand the information provided in the ICF and has signed the ICF.
  • Subject is a current non-daily user of nicotine pouches (past 30-day use) based on self-reported tobacco/nicotine-containing product use history.
  • Subject expresses no desire to quit consumer nicotine product use within the next 3 months from Screening visit.

Exclusion criteria

Exclusion Criteria:

  • Subject uses or intents to start using nicotine replacement therapy or any other medication for smoking cessation.
  • Subject uses other consumer nicotine products besides nicotine pouches more frequently than once per 30 days.
  • Subject with a urine cotinine test exceeding 500 ng/mL.
  • Subject has exhaled CO reading ≥ 10 ppm.
  • Subject has reasons other than medical (e.g., psychological, social reason) to not participate in the study, as determined by the Investigator.
  • Subject has a disease which requires medication or any other medical condition including clinically significant safety laboratory parameters at Screening visit, as determined by the Investigator.
  • Subject has a positive serology test for 1/2, or C.
  • Subject has a positive urine drug test.
  • Subject has a positive urine alcohol test.
  • Subject has a visual or motor impairment that would interfere with their ability to perform a computer-based attentional task.
  • Subject has a current prescription for medical use of cannabis, any use of cannabis products in the past month, or inability to refrain from cannabis use during the Screening and Testing visits. For clarification, use of non-psychoactive cannabis-derived products which contain only cannabidiol is not considered to be cause for exclusion.
  • Subject has used any medication, drugs, or substances that could affect cognitive processing such as antidepressants, antipsychotics, sedatives, stimulants, and hallucinogens within the past six months prior to Screening visit.
  • Subject or one of their family members is an employee of the site or of any other parties involved in the study.
  • Subject has participated in another clinical study within 30 days prior to the Screening visit or concomitantly participates in an investigational study involving no drug or device administration.
  • For female subjects only: subject is pregnant (does not have negative pregnancy tests at Screening visit or Visit 2 or breastfeeds.
  • For female subjects of only: subject does not agree to use an acceptable method of effective .
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
40 participants (actual)

Study arms

  • Active comparator
    Product Sequence 1

    The list of possible sequences are: NT-0mg; NT-0.5mg; NT-1.0mg; NT-1.5mg; NT-2.0mg

    Other: NICOTINE TABLET-0mg · Other: NICOTINE TABLET-0.5mg · Other: NICOTINE TABLET-1.0mg · Other: NICOTINE TABLET-1.5mg · Other: NICOTINE TABLET-2.0mg

  • Active comparator
    Product Sequence 2

    The list of possible sequences are: NT-0mg; NT-0.5mg; NT-1.0mg; NT-1.5mg; NT-2.0mg

    Other: NICOTINE TABLET-0mg · Other: NICOTINE TABLET-0.5mg · Other: NICOTINE TABLET-1.0mg · Other: NICOTINE TABLET-1.5mg · Other: NICOTINE TABLET-2.0mg

  • Active comparator
    Product Sequence 3

    The list of possible sequences are: NT-0mg; NT-0.5mg; NT-1.0mg; NT-1.5mg; NT-2.0mg

    Other: NICOTINE TABLET-0mg · Other: NICOTINE TABLET-0.5mg · Other: NICOTINE TABLET-1.0mg · Other: NICOTINE TABLET-1.5mg · Other: NICOTINE TABLET-2.0mg

  • Active comparator
    Product Sequence 4

    The list of possible sequences are: NT-0mg; NT-0.5mg; NT-1.0mg; NT-1.5mg; NT-2.0mg

    Other: NICOTINE TABLET-0mg · Other: NICOTINE TABLET-0.5mg · Other: NICOTINE TABLET-1.0mg · Other: NICOTINE TABLET-1.5mg · Other: NICOTINE TABLET-2.0mg

  • Active comparator
    Product Sequence 5

    The list of possible sequences are: NT-0mg; NT-0.5mg; NT-1.0mg; NT-1.5mg; NT-2.0mg

    Other: NICOTINE TABLET-0mg · Other: NICOTINE TABLET-0.5mg · Other: NICOTINE TABLET-1.0mg · Other: NICOTINE TABLET-1.5mg · Other: NICOTINE TABLET-2.0mg

Interventions

  • OtherNICOTINE TABLET-0mg

    NICOTINE TABLET (nicotine content 0mg; Mint flavor)

  • OtherNICOTINE TABLET-0.5mg

    NICOTINE TABLET (nicotine content 0.5mg; Mint flavor)

  • OtherNICOTINE TABLET-1.0mg

    NICOTINE TABLET (nicotine content 1.0mg; Mint flavor)

  • OtherNICOTINE TABLET-1.5mg

    NICOTINE TABLET (nicotine content 1.5mg; Mint flavor)

  • OtherNICOTINE TABLET-2.0mg

    NICOTINE TABLET (nicotine content 2.0mg; Mint flavor)

06

What researchers measure

Primary outcomes

  1. Change in attentional performance after 15 minutes

    To evaluate the effect of nicotine on attentional performance following a 10-minute use of five NICOTINE TABLET variants containing 0 mg, 0.5 mg, 1.0 mg, 1.5 mg, or 2.0 mg nicotine. Attentional performance will be assessed 15 minutes after the start of product use using the Conners Continuous Performance Test (CPT).

    Time frame: 15 minutes after the start of product use

Secondary outcomes

  1. Change in attentional performance after 2 hours

    To evaluate the effect of nicotine on attentional performance following a 10-minute use of five NICOTINE TABLET variants containing 0 mg, 0.5 mg, 1.0 mg, 1.5 mg, or 2.0 mg nicotine. Attentional performance will be assessed 2 hours after the start of product use using the Conners Continuous Performance Test (CPT).

    Time frame: 2 hours after the start of product use

  2. Change in self-reported craving for nicotine pouch use

    Participants will rate their craving on a 100 mm unipolar scale (0 = no craving, 100 = strong craving) in response to the question: "How strong is your craving for using a nicotine pouch?" following a 10-minute use of five NICOTINE TABLET variants containing 0 mg, 0.5 mg, 1.0 mg, 1.5 mg, or 2.0 mg nicotine.

    Time frame: 10 minutes after the start of product use

07

Study locations

1 site
  • CTC Clinical Trial Consultants AB
    Uppsala, 752 37, Sweden
08

References and documents

Publications

  • Shaked D, Faulkner LMD, Tolle K, Wendell CR, Waldstein SR, Spencer RJ. Reliability and validity of the Conners' Continuous Performance Test. Appl Neuropsychol Adult. 2020 Sep-Oct;27(5):478-487. doi: 10.1080/23279095.2019.1570199. Epub 2019 Feb 22. PubMed 30793982 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2025 to primary completion in Mar 2026, 4 months.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 5, 2026
First posted
Feb 13, 2026
StartActual
Oct 28, 2025
Primary completionActual
Mar 16, 2026
CompletionActual
Apr 23, 2026
Last update
May 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 5, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07408180
Responsible party
Sponsor
First posted
Feb 13, 2026
Start date
Oct 28, 2025
Primary completion
Mar 16, 2026
Completion
Apr 23, 2026
Last update
May 5, 2026

Study contacts

Xavier Jaumont, MD
study chair · Philip Morris Products S.A.

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion